Ceragenin CSA-13 induces cell cycle arrest and antiproliferative effects in wild-type and p53 null mutant HCT116 colon cancer cells

Anti-Cancer Drugs

Volumn 24, Issue 8, 2013, Pages 826-834

  Kuroda, Kengo ^a   Fukuda, Tomokazu ^a   Okumura, Kazuhiko ^b   Yoneyama, Hiroshi ^a   Isogai, Hiroshi ^c   Savage, Paul B ^d   Isogai, Emiko ^a  

^a TOHOKU UNIVERSITY   (Japan)

^b HEALTH SCIENCES UNIVERSITY OF HOKKAIDO   (Japan)

^c SAPPORO MEDICAL UNIVERSITY   (Japan)

^d Brigham Young University   (United States)

Author keywords

antiproliferative; apoptosis; cell cycle; ceragenin; colon cancer; CSA 13; p53 gene

Indexed keywords

ANTINEOPLASTIC AGENT; CATHELICIDIN; CSA 13; UNCLASSIFIED DRUG;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE; CELL CYCLE ARREST; CELL GROWTH; CELL PROLIFERATION; CELL STRAIN HCT116; COLON CANCER; HUMAN; HUMAN CELL; MITOCHONDRIAL MEMBRANE; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; WILD TYPE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASES; CELL PROLIFERATION; COLONIC NEOPLASMS; DNA FRAGMENTATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; G1 PHASE CELL CYCLE CHECKPOINTS; HCT116 CELLS; HUMANS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MUTATION; STEROIDS; TIME FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84881044619     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3283634dd0     Document Type: Article

References (40)

1. Tjabringa GS, Vos JB, Olthuis D, Ninaber DK, Rabe KF, Schalkwijk J, et al. Host defense effector molecules in mucosal secretions. FEMS Immunol Med Microbiol 2005; 45:151-158.
2. Zanetti M, Gennaro R, Scocchi M, Skerlavaj B. Structure and biology of cathelicidins. Adv Exp Med Biol 2000; 479:203-218.
3. Cowland JB, Johnsen AH, Borregaard N. hCAP-18, a cathelin/pro-bactenecin- like protein of human neutrophil specific granules. FEBS Lett 1995; 368:173-176.
4. Sorensen O, Arnljots K, Cowland JB, Bainton DF, Borregaard N. The human antibacterial cathelicidin, hCAP-18, is synthesized in myelocytes and metamyelocytes and localized to specific granules in neutrophils. Blood 1997; 90:2796-2803.
5. Agerberth B, Gunne H, Odeberg J, Kogner P, Boman HG, Gudmundsson GH. FALL-39, a putative human peptide antibiotic, is cysteine-free and expressed in bone marrow and testis. Proc Natl Acad Sci USA 1995; 92:195-199.
6. Chen PH, Fang SY. The expression of human antimicrobial peptide LL-37 in the human nasal mucosa. Am J Rhinol 2004; 18:381-385.
7. Murakami M, Ohtake T, Dorschner RA, Gallo RL. Cathelicidin antimicrobial peptides are expressed in salivary glands and saliva. J Dent Res 2002; 81:845-850.
8. Bals R, Wang X, Zasloff M, Wilson JM. The peptide antibiotic LL-37/hCAP-18 is expressed in epithelia of the human lung where it has broad antimicrobial activity at the airway surface. Proc Natl Acad Sci USA 1998; 95:9541-9546.
9. Oren Z, Lerman JC, Gudmundsson GH, Agerberth B, Shai Y. Structure and organization of the human antimicrobial peptide LL-37 in phospholipid membranes: relevance to the molecular basis for its non-cell-selective activity. Biochem J 1999; 341 (Pt 3):501-513.
10. Brogden KA. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nat Rev Microbiol 2005; 3:238-250.
11. Lai XZ, Feng Y, Pollard J, Chin JN, Rybak MJ, Bucki R, et al. Ceragenins: cholic acid-based mimics of antimicrobial peptides. Acc Chem Res 2008; 41:1233-1240.
12. Pollard JE, Snarr J, Chaudhary V, Jennings JD, Shaw H, Christiansen B, et al. In vitro evaluation of the potential for resistance development to ceragenin CSA-13. J Antimicrob Chemother 2012; 67:2665-2672.
13. Okumura K, Itoh A, Isogai E, Hirose K, Hosokawa Y, Abiko Y, et al. C-terminal domain of human CAP18 antimicrobial peptide induces apoptosis in oral squamous cell carcinoma SAS-H1 cells. Cancer Lett 2004; 212:185-194.
14. Kuroda K, Fukuda T, Yoneyama H, Katayama M, Isogai H, Okumura K, et al. Anti-proliferative effect of an analogue of the LL-37 peptide in the colon cancer derived cell line HCT116 p53 +/+ and p53. Oncol Rep 2012; 28:829-834.
15. Van Cutsem E, Geboes K. The multidisciplinary management of gastrointestinal cancer. The integration of cytotoxics and biologicals in the treatment of metastatic colorectal cancer. Best Pract Res Clin Gastroenterol 2007; 21:1089-1108.
16. Li Z, Song H, He W, Tian Y, Huang T. In vitro chemosensitivity testing of primary and recurrent breast carcinomas and its clinical significance. J Huazhong Univ Sci Technolog Med Sci 2008; 28:683-687.
17. Yanagawa E, Nishiyama M, Saeki T, Kim R, Jinushi K, Kirihara Y, et al. Chemosensitivity tests in colorectal cancer patients. Jpn J Surg 1989; 19:432-438.
18. Deslouches B, Islam K, Craigo JK, Paranjape SM, Montelaro RC, Mietzner TA. Activity of the de novo engineered antimicrobial peptide WLBU2 against Pseudomonas aeruginosa in human serum and whole blood: implications for systemic applications. Antimicrob Agents Chemother 2005; 49: 3208-3216.
19. Chin JN, Rybak MJ, Cheung CM, Savage PB. Antimicrobial activities of ceragenins against clinical isolates of resistant Staphylococcus aureus. Antimicrob Agents Chemother 2007; 51:1268-1273.
20. Leszczynska K, Namiot A, Fein DE, Wen Q, Namiot Z, Savage PB, et al. Bactericidal activities of the cationic steroid CSA-13 and the cathelicidin peptide LL-37 against Helicobacter pylori in simulated gastric juice. BMC Microbiol 2009; 9:187.
21. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 1998; 282:1497-1501.
22. Leytin V, Allen DJ, Mutlu A, Gyulkhandanyan AV, Mykhaylov S, Freedman J. Mitochondrial control of platelet apoptosis: effect of cyclosporin A, an inhibitor of the mitochondrial permeability transition pore. Lab Invest 2009; 89:374-384.
23. Philpott NJ, Turner AJ, Scopes J, Westby M, Marsh JC, Gordon-Smith EC, et al. The use of 7-amino actinomycin D in identifying apoptosis: simplicity of use and broad spectrum of application compared with other techniques. Blood 1996; 87:2244-2251.
24. Koopman G, Reutelingsperger CP, Kuijten GA, Keehnen RM, Pals ST, van Oers MH. Annexin V for flow cytometric detection of phosphatidyl-serine expression on B cells undergoing apoptosis. Blood 1994; 84: 1415-1420.
25. Zelenin AV, Poletaev AI, Stepanova NG, Barsky VE, Kolesnikov VA, Nikitin SM, et al. 7-Amino-actinomycin D as a specific fluorophore for DNA content analysis by laser flow cytometry. Cytometry 1984; 5:348-354.
26. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972; 26:239-257.
27. Shanmugam MK, Kannaiyan R, Sethi G. Targeting cell signaling and apoptotic pathways by dietary agents: role in the prevention and treatment of cancer. Nutr Cancer 2011; 63:161-173.
28. Zamzami N, Marchetti P, Castedo M, Decaudin D, Macho A, Hirsch T, et al. Sequential reduction of mitochondrial transmembrane potential and generation of reactive oxygen species in early programmed cell death. J Exp Med 1995; 182:367-377.
29. Errami Y, Naura AS, Kim H, Ju J, Suzuki Y, El-Bahrawy AH, et al. Apoptotic DNA fragmentation may be a cooperative activity between caspase-activated DNASE and the PARP-regulated DNAS1L3, an ER-localized endonuclease that translocates to the nucleus during apoptosis. J Biol Chem 2013; 288:3460-3468.
30. Favaloro B, Allocati N, Graziano V, Di Ilio C, De Laurenzi V. Role of apoptosis in disease. Aging (Albany NY) 2012; 4:330-349.
31. Lane DP, Lain S. Therapeutic exploitation of the p53 pathway. Trends Mol Med 2002; 8:S38-S42.
32. Hartwell LH, Culotti J, Pringle JR, Reid BJ. Genetic control of the cell division cycle in yeast. Science 1974; 183:46-51.
33. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75: 817-825.
34. Russo A, Esposito D, Catillo M, Pietropaolo C, Crescenzi E, Russo G. Human rpL3 induces G(1)/S arrest or apoptosis by modulating p21 (waf1/cip1) levels in a p53-independent manner. Cell Cycle 2013; 12: 76-87.
35. Yang X, Wang W, Qin JJ, Wang MH, Sharma H, Buolamwini JK, et al. JKA97, a novel benzylidene analog of harmine, exerts anti-cancer effects by inducing G1 arrest, apoptosis, and p53-independent up-regulation of p21. PLoS One 2012; 7:e34303.
36. Liu X, Kim CN, Yang J, Jemmerson R, Wang X. Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell 1996; 86:147-157.
37. Degterev A, Yuan J. Expansion and evolution of cell death programmes. Nat Rev Mol Cell Biol 2008; 9:378-390.
38. Kitanaka C, Kuchino Y. Caspase-independent programmed cell death with necrotic morphology. Cell Death Differ 1999; 6:508-515.
39. Clarke PG. Developmental cell death: morphological diversity and multiple mechanisms. Anat Embryol (Berl) 1990; 181:195-213.
40. Zakeri Z, Bursch W, Tenniswood M, Lockshin RA. Cell death: programmed, apoptosis, necrosis, or other? Cell Death Differ 1995; 2:87-96.